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Chronic active type B gastritis is invariably the result of Helicobacter pylori
infection and is an important factor in duodenal ulcer disease. The actions of
mediators produced (a protein factor, a lipid soluble "pore-forming factor" and
urease) or induced (immune/inflammatory cell mediators) by this bacterium on
the control of gastric acid secretion are currently being investigated. These
studies are reviewed in light ofour current knowledge of the physiological con-
trol ofgastric acid secretion.
INTRODUCTION
It is now generally accepted that human infection of the gastric antrum with
Helicobacter pylori is the most important cause of histological type B chronic active
antral gastritis, with almost a 100 percent association between H. pylori infection and
antral gastritis [1, 2]. H. pylori is a curved, S-shaped, motile, microaerophilic, Gram-neg-
ative rod, which is 2.5 gm long and 0.5 gm in diameter and has four to six unipolar
sheathed flagella [3]. It lives adjacent to the gastric epithelium underlying the mucus
bicarbonate layer in the human stomach, adherent to the gastric epithelial cell and within
areas ofgastric metaplasia [4-6].
A number ofstudies provide strong evidence to support the hypothesis that H. pylori
plays an important etiological role in duodenal ulcer disease. Thus, H. pylori is found in
95 to 100 percent of duodenal ulcer patients [7-9]. Furthermore, the relative risk of a
number offactors in duodenal ulcer disease have been quantified: duodenal gastric meta-
plasia, antral H. pylori and duodenal H. pylori yielded relative risk values of 6.22, 7.67
and 51.0, respectively [10]. Finally, eradication of H. pylori reverses chronic active gas-
tritis and reduces the one-year duodenal ulcer relapse rate to virtually zero [11]. It should
be noted, however, that only a minority of H. pylori-infected individuals develop duode-
nal ulcers [12]; therefore, this bacterium is probably not solely responsible for duodenal
ulcer formation. Rather, H. pylori infection should be viewed as an important contribut-
ing factor to the pathophysiology ofduodenal ulcer disease.
It is generally accepted that duodenal ulcer patients secrete more gastric acid than
normal individuals [13]. Recent studies have examined the effects of H. pylori and H.
pylori-induced inflammation on gastric acid secretion. These recent studies are reviewed
in light ofour current understanding ofthe physiological mechanisms that are involved in
the control ofgastric acid secretion.
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H. PYLORI AND GASTRIC ACID SECRETION
The effect of H. pylori infection on gastric acid secretion appears to be complex and
probably depends on the stage of infection. Hypochlorhydria may occur in the early
stages of infection with this bacterium (for review see Ref. 14). Later in H. pylori infec-
tion, hypersecretion of gastric acid probably occurs, at least in individuals who have
developed duodenal ulcers. This is supported by recent studies in which well-defined
populations of H. pylori-negative, normal volunteers and H. pylori-positive, duodenal
ulcer patients were used to study acid secretion. These studies demonstrated significantly
greater basal and maximum pentagastrin- and gastrin-releasing, peptide-stimulated acid
output in the duodenal ulcer group than in the control group [15, 16]. Furthermore, eradi-
cation ofH. pylori in duodenal ulcer patients resulted in decreased acid secretion [15-17].
H. pylori andhyposecretion ofgastric acid
H. pylori produces a number of compounds that directly inhibit acid secretion. This
was first suggested in studies in which application ofH. pylori to isolated guineapig pari-
etal cell or isolated rabbit gastric gland preparations resulted in an inhibition of acid
secretion as measured indirectly by the accumulation of the weak base 14C-aminopyrine
[18, 19]. The inhibition of acid secretion apparently occurs via two factors produced by
H. pylori: a protein factor [19] and a lipid soluble "pore-forming factor" [20], possibly
tetradecanoic acid, which is found in large amounts in H. pylori [21]. Whether these com-
pounds alter acid secretion in vivo has been questioned by Danon et al. [22] who found
that large numbers of H. pylori are needed to inhibit acid secretion in the isolated rabbit
parietal cell preparation and that the effect can be mimicked by sonicates from a number
of other bacteria. Interestingly, Jablonowski et al. [23] have recently reported that H.
pylori sonicates from gastritis patients inhibited acid secretion in isolated human gastric
glands more effectively than those from duodenal ulcer patients. Whether these H. pylon-
factors act only on the parietal cell or whether they also act on other cell types involved
in the control of acid secretion (nerves, mast cells, ECLb cells, D cells, G cells, etc.) is not
known.
The immune/inflammatory response of the host to H. pylori infection may also alter
gastric acid secretion (for recent review see Ref. 24). In this regard, H. pylori infection
results in gastric mucosal infiltration with neutrophils, eosinophils, basophils,
macrophages, monocytes, plasma cells and mast cells [12]. Together, these
immune/inflammatory cells are known to release a variety of mediators, including
immunoglobulins, biogenic amines, purines, eicosanoids, platelet-activating factor, reac-
tive oxygen metabolites and cytokines. The present discussion is restricted to recent stud-
ies concerning the effects of cytokines on acid secretion. There are over 30 known
cytokines [25], but ofthese, only a few have been studied with respect to H. pylori infec-
tion. Thus, the levels of interleukin (IL)-1, IL-6, IL-8 and tumor necrosis factor (TNF)-a
have been shown to be higher in H. pylori-positive than H. pylori-negative human antral
biopsies [26, 27]. Furthermore, interferon (IFN)-y production has been shown to be
induced by contact oflymphocytes with H. pylori in vitro [28].
IL-I is produced by activated macrophages/monocytes and other cell types and
released during immune/inflammatory processes [29-31], H. pylori-induced gastritis being
no exception [27]. It has many biological actions, which may be involved in acute
immune/inflammatory processes (for review see Refs. 29-31). Uehara et al. [32] were the
first to show that IL-1, in very low concentrations, causes prolonged inhibition of basal
acid secretion in the pylorus-ligated rat preparation. This finding has been confirmed [33-
39]. Central administration of IL-1 results in inhibitory effects at 100-1000 times lower
concentrations than required for effects by peripheral administration. Centrally, the actions
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of IL-I appear to involve prostaglandins and the vagus nerve, but not the central adrener-
gic nervous system, corticotropin releasing factor or the adrenal glands [38, 39].
Peripherally, prostaglandins and IL-I receptors appear to be involved, but not corticotropin
releasing factor, somatostatin or capsaicin-sensitive afferent nerves [32-34]. In the pylorus-
ligated, urethane-anaesthetized rat preparation, IL-1 selectively inhibits pentagastrin-stim-
ulated histamine release [35]; this effect involves nitric oxide [40]. In the isolated canine
gastric parietal cell preparation, IL-I inhibits histamine- and carbachol-mediated acid
secretion by acting directly on the parietal cell [41].
IL-I has also been studied in a number of rat models of acute gastrointestinal dam-
age. It reduced gastrointestinal damage due to water-immersion restraint stress [36, 37,
42], thyrotropin releasing hormone [43], ethanol [43-45], non-steroidal, anti-inflammato-
ry drugs (NSAID) [44-47] and cysteamine [44]. Central prostaglandins, but not corti-
cotropin releasing factor, appear to be involved in the effects ofIL-I in the water-immer-
sion stress model [36, 37, 42]. Endogenous prostaglandins and inhibition of acid secre-
tion appear to be involved in the ethanol model ofgastric damage [44]. Although the later
mechanisms may also be involved in the effects of IL-I on NSAID-induced gastric dam-
age, interactions with endogenous glucocorticoids [46], and inhibition ofneutrophil func-
tion may also play a role [47].
A number of other cytokines, which are increased by H. pylori infection, have also
been studied with respect to gastric acid secretion. In this regard, TNF-a does not alter
secretagogue-stimulated acid secretion [35] or NSAID-induced gastropathy [47] in the
rat, although it shares many other biological actions with IL-1 [30]. On the other hand,
acid secretion is inhibited by this cytokine in the isolated canine parietal cell preparation
[41] and the isolated murine gastric gland preparation (Muller, Padol and Hunt, unpub-
lished observation). The potent neutrophil chemotactic agent IL-8 [48] also inhibits acid
secretion in the isolated murine gastric gland preparation (Muller, Padol, Ernst and Hunt,
unpublished observation). It is selectively released from epithelial cells by co-culturing
H. pylori with the gastric adenocarcinoma cell line KATO III, suggesting that the gastric
epithelium may initiate neutrophil recruitment and local inflammation [49]. We have
recently shown that IFN-y inhibits secretagogue-stimulated acid secretion in the isolated
murine gastric gland preparation [50]. This effect was concentration-dependent, rapid,
non-competitive and selectively blocked by rat anti-mouse IFN-y antibodies [50]. Taken
together, these results, and the above-mentioned demonstration that IFN-y, TNF-a and
IL-8 levels are elevated by H. pylori, suggest that these cytokines may be involved in the
down-regulation of acid secretion in the early stages of infection by this bacterium. The
potential roles ofTNF-a, IL-8 and IFN-yin H. pylori infection require further study.
Some cytokine growth factors also inhibit gastric acid secretion and reduce gastroin-
testinal damage in rat models. Epidermal growth factor (EGF), originally characterized as
urogastrone [51], is a good example [51-57]. A novel EGF-producing cell lineage devel-
ops in the setting ofchronic ulceration [58, 59]. Active duodenal ulcers have been associ-
ated with a decrease in the levels ofgastricjuice EGF [60]. Transforming growth factor-
a, which appears to be normally produced by parietal cells [61, 62], also inhibits gastric
acid secretion [63-65], and protects in animal models ofgastrointestinal damage [57].
In summary, an early response ofthe host to infection by H. pylori appears to be sup-
pression of gastric acid secretion, which probably aids in bacterial colonization. A num-
ber of compounds produced by H. pylori (a protein factor, a lipid soluble "pore-forming
factor") and by the host (cytokines) in response to bacterial infection have recently been
shown to be able to inhibit gastric acid secretion. The control of gastric acid secretion is
complex, involving neural (cholinergic nerves), endocrine (gastrin), paracrine (histamine
and somatostatin) and autocrine (prostaglandins) influences (for recent reviews see Refs.
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66-68); each of these influences, in turn, is controlled by multiple physiologic processes.
The parietal cell appears to be the site of action of many of these acid inhibitory com-
pounds, although preliminary studies suggest that other cell types may also be involved,
i.e., ECL cells and the central nervous system. No data are available concerning the
effects of these acid inhibitory compounds on cholinergic nerves, which are involved in
the control of acid secretion. Much remains to be learned about where (which cell types)
and how (receptor and post-receptor mechanisms) these compounds inhibit gastric acid
secretion.
H. pylori and hypersecretion ofgastric acid
A number of studies have now shown that H. pylori-positive individuals have higher
fasting and meal-induced serum gastrin levels than H. pylori-negative controls [69-72]
and that eradication of H. pylori results in the return of gastrin levels to normal [17, 69,
72, 73]. Gastrin is the main stimulus for meal-stimulated acid secretion, and it exerts
trophic effects on a number of gastric mucosal cells, including parietal cells, chief and
ECL cells.
The first working hypothesis to explain H. pylori-induced hypersecretion of gastric
acid was the "Gastrin Link" hypothesis [69, 74]. This hypothesis suggested that urease
produced by H. pylori increases gastrin release by converting urea to ammonia and thus
raising the pH in the vicinity of G cells. Recent studies, concerning the effects of antral
alkalinization on basal and meal-stimulated gastrin levels in duodenal ulcer patients
before and after eradication of H. pylori, provide strong evidence that the hypergastri-
naemia is not due to elevated antral surface pH [75, 76]. It is not known whether bacterial
products, other than urease, are involved in H. pylori-associated hypergastrinaemia.
A number of studies suggest that the hypergastrinaemia associated with H. pylori
infection may be caused by the immune/inflammatory response to the bacterium. Thus,
systemically immunized dogs showed a significant increase in gastrin levels with an oral
challenge by specific human gamma globulin in comparison to controls [77]. A more
recent study showed that mononuclear cells, but not H. pylori, release gastrin from cul-
tured G cells via diffusible factors [78]. In vitro studies have shown that IL-1, IL-2 and
IFN-y cause gastrin release [79, 80]. In cultured canine antral G cells, IFN-y and TNF-a
have been shown to release gastrin [81]. TNF-a also released gastrin from human antral
biopsies [82].
The physiological control of gastrin secretion in the normal gastric antrum is com-
plex, involving neural (cholinergic, vasoactive intestinal polypeptide and bombesin/gas-
trin-releasing peptide nerves), paracrine (somatostatin) and luminal factors (small pep-
tides, amino-acid fragments and gastric acidity) as well as gastric motility; several excel-
lent reviews are available [67, 68, 83, 84]. Any one or any combination of these mecha-
nisms could potentially be altered by H. pylori-produced and/or H. pylori-induced prod-
ucts. Recent studies have focused on somatostatin.
The possibility has been raised that the D cell, which provides a tonic "brake" on
gastrin release, might be involved in H. pylori-induced changes in gastrin release. In this
regard, although the density ofantral G cells is not different in H. pylori-infected individ-
uals as compared to H. pylori-negative controls [85, 86], the density of antral D cells and
the D:G cell ratio is decreased in the experimental group [85, 87]. Also, the concentration
of immunoreactive-somatostatin is decreased in the human stomach during H. pylori
infection [88]. Moreover, eradication of H. pylori significantly increases antral D cell
density [89, 90]. Together, these studies suggest that a decrease in the "braking" mecha-
nism for gastrin release may be responsible for the increased gastrin release observed in
H. pylori infection. It should be noted, however, that a decreased density of D cells in
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H. pylori-positive patients has not been found by other investigators [91]. Thus, the effect
of H. pylori infection on D cell density is controversial, perhaps due to methodological
difficulties associated with measuring D cell densities. Interestingly, preliminary reports
have suggested that chronic administration of ammonia to rats decreases antral D cell
density and somatostatin concentration [92] and that TNF-a inhibits somatostatin secre-
tion in human antral biopsies [82]. Clearly, the role ofD cells in H. pylori-associated gas-
tritis and duodenal ulcer disease requires further investigation.
In summary, H. pylori-induced hypergastrinaemia may contribute to gastric acid
hypersecretion in duodenal ulcer patients. One hypothesis is that the normal negative-
feedback mechanism for gastrin secretion is interrupted by the production of base by H.
pylori-derived urease in the vicinity of antral D- and G cells. Another hypothesis is that
mediators of the immune/inflammatory response to H. pylori act on the G- and/or D cell
to increase gastrin secretion. Yet another hypothesis is that D cell density is decreased in
H. pylori infection, resulting in a decrease in the "braking" mechanism for gastrin release.
Future studies, aimed at testing these hypotheses, will undoubtedly add tremendously to
our understanding ofimmunophysiological processes in the stomach.
SIGNIFICANCE AND CONCLUSIONS
H. pylori-induced changes in gastric acid secretion probably play an important role
in the development of duodenal ulcers. In the early stages of H. pylori infection, acid
hyposecretion would aid in bacterial colonization ofthe gastric antrum. H. pylori-induced
hypergastrinaemia probably causes acid hypersecretion directly, by stimulating acid
secretion at the level of the parietal cell and by releasing histamine from ECL cells and
mast cells, and indirectly, by causing hypertrophy of parietal cells and ECL cells.
Increased acid secretion would cause gastric metaplasia in the duodenal cap and allow H.
pylori to colonize the duodenum, where the bacterially induced inflammation, together
with acid, would cause duodenitis. Eventually, a duodenal ulcer could develop as a result
of a combination of the following processes: H. pylori-induced decrease in mucosal
defense mechanisms (mucus, bicarbonate, prostaglandins and blood flow); H. pylori-
induced increase in aggressive factors (acid, as already discussed, and pepsinogens [acti-
vated to pepsins] via gastrin-mediated hypertrophy of chief cells and H. pylori-derived
lipopolysaccharide); direct damage to the mucosa by urease, cytotoxin and other H.
pylori-derived products.
From the above discussion, a number of conclusions can be drawn and questions
asked about the effects of H. pylori on gastric acid secretion. H. pylori produces com-
pounds, such as a protein factor and a lipid soluble "pore-forming factor," which decrease
acid secretion, as well as urease, which increases acid secretion. The level of some
immune/inflammatory mediators (IL-1, IL-6, IL-8, TNF-a and IFN-y) are increased by
H. pylori; however, most cytokines have not yet been studied in this regard. In the gastric
fundus, many of these cytokines appear to decrease acid secretion. In the gastric antrum,
at least some ofthese compounds may increase acid secretion by increasing gastrin secre-
tion and/or by decreasing somatostatin secretion. No cytokines or H. pylori-produced fac-
tors have yet been reported to increase acid secretion by acting on parietal cells, ECL
cells, mast cells or D cells in the gastric fundus or to decrease acid secretion by acting on
G or D cells in the gastric antrum. Whether H. pylori-induced cytokines or H. pylori-pro-
duced factors alter acid secretion by altering neurotransmitter release anywhere in the
stomach has not yet been investigated.
The realization that H. pylori may play a central role in the regulation ofgastric acid
secretion and that this contributes to the pathogenesis ofduodenal ulcer disease has been
the impetus for many recent investigations concerned with the immunophysiology of
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gastric secretions. It is apparent that the stomach is similar to the rest ofthe gastrointesti-
nal tract, since it is in a constant state of inflammation in a large percentage of the popu-
lation: approximately 50 percent of the population in the industrialized world is infected
with H. pylori by the age of 60 [93]. We are just beginning to ask important questions
(who, what, where, when and why) about the H. pylori-mediated control of gastric acid
secretion. As a result, our understanding and concepts of the regulation of gastric acid
secretion is rapidly changing.
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